42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)
Year: 2021
Type: article
Source: Annals of Oncology
Institutions: Harvard University, Dana-Farber Cancer Institute, Roche (Switzerland), Genentech, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Clinica Universidad de Navarra, Ludwig-Maximilians-Universität München, Seoul National University, Seoul National University Hospital, Hospital São Lucas da PUCRS, Pontifícia Universidade Católica do Rio Grande do Sul, Université de Bordeaux, Institut Bergonié, Seattle Cancer Care Alliance, University of Washington, Guy's Hospital, Sarah Cannon Research Institute, Fondazione Michelangelo, Kyoto University, Georgetown University Medical Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: F. Hoffmann-La Roche
OpenAlex ID: W3160068776